Journals / Turkish Journal of Medical Sciences / 2022 / Cilt: 52 - Sayı: 3

Investigation of miRNA and cytokine expressions in latent tuberculosis infection and active tuberculosis

Pages
649–657
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: There is no significant relationship between the clinical course of the disease, cytokine and miRNA expression, and the genotype of the bacteria.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: In tuberculsosis (TB), miRNA has been used as a biomarker to distinguish between healthy individuals and TB patients.
📊
Key Findings & Data:Materials and methods: A total of 200 cases (100: culture positive active tuberculosis, 50: quantiferon positive latent tuberculosis infection and 50: quantiferon negative healthy controls) were included in the study.
💡
Conclusion & Impact:Conclusion: There is no significant relationship between the clinical course of the disease, cytokine and miRNA expression, and the genotype of the bacteria.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: In tuberculsosis (TB), miRNA has been used as a biomarker to distinguish between healthy individuals and TB patients. The aim of this study was to investigate (i) the association of the miRNA and cytokine expression levels, the course of tuberculosis infection, clinical forms and response to treatment, and (ii) the effects of genotypic features of bacteria on the course of tuberculosis and the relationship between miRNA and cytokine expressions and bacterial genotypes. Materials and methods: A total of 200 cases (100: culture positive active tuberculosis, 50: quantiferon positive latent tuberculosis infection and 50: quantiferon negative healthy controls) were included in the study. For the tuberculosis group at the time of admission and after treatment, for the latent tuberculosis infection and healthy control groups at the time of admission, miRNA and cytokine expressions were determined. Genotyping of M.tuberculosis isolates was performed by spoligotyping method. Results: While, in the comparison of miRNA expressions between the pretreatment patient group and the healthy control group, there was a statistically significant decrease in the expression of miR-454-3p, miR-15a-5p, miR-590-5p, miR-381, and miR-449a in the Pulmonary TB group, there was no significant change in miRNA expression in extrapulmonary TB patients. When the cytokine expressions of the patient group and the healthy control group were compared before treatment, the expressions of all cytokines in the patient group decreased. However, the only cytokine that showed a significantly lower expression was IL12A in PTB patients. Conclusion: There is no significant relationship between the clinical course of the disease, cytokine and miRNA expression, and the genotype of the bacteria.

🔖

Cite This Article

GÜNDÜZ, C., YILMAZ, F. F., BİÇMEN, C., KARAMAN, O., AKARCA, T., DERELİ, Ş., AKIN, H., CENGİSİZ, Z., DURMAZ, A., TAŞLIDERE, H., ÇAVUŞOĞLU, C., TAŞBAKAN, M. S., ÇOĞULU, Ö., TAŞBAKAN, M. (2022). Investigation of miRNA and cytokine expressions in latent tuberculosis infection and active tuberculosis. Turkish Journal of Medical Sciences, Cilt: 52 - Sayı: 3, 649–657. https://ajindex.com/articles/609275

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Global Tuberculosis Report 2018 ISBN 978-92-4-156564-6 © World Health Organization 2018. Printed in France WHO/ CDS/TB/2018.20
  2. Çavuşoğlu C. History of tuberculosis and tuberculosis control program in Turkey. Microbiology Australia 2014; 35: 169-173
  3. TC Sağlık Bakanlığı, Tüberküloz Tanı ve Tedavi Rehberi. Artı6 Medya Tanıtım Matbaa Ltd. Sti
  4. Baskı Ankara; 2019
  5. McNerney R, Maeurer M, Abubakar I, Marais B, McHugh TD et al. Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. Journal of Infectious Disease 2011; 205: 147-158. doi: 10.1093/infdis/ jir860 5. Norbis L, Miotto P, Alagna R, Cirillo DM. Tuberculosis: lights and shadows in the current diagnostic landscape. New Microbiology 2013; 36 (2): 111-120. doi: 10.1186/1758-2652- 13-40 6. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Immunological biomarkers of tuberculosis. Nature Reviews Immunology 2011; 11 (5): 343-354. doi: 10.1038/nri2960 7. Wallis RS, Kim P, Cole S, Hanna D, Andrade BB et al. Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infectious Diseases 2013; 13 (4): 362-372. doi: 10.1016/S1473-3099(13)70034-3 8. Wallis RS, Wang C, Doherty TM, Onyebujoh P, Vahedi M et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infectious Diseases 2010; 10 (2): 68-69. doi: 10.1016/ S1473-3099(09)70042-8 9. Miotto P, Mwangoka G, Valente IC, Norbis L, Sotgiu G et al. miRNA signatures in sera of patients with active pulmonarytuberculosis. PLoS One 2013; 8 (11): e80149. doi: 10.1371/journal.pone.0080149 10. Lawn SD, Zumla AI. Tuberculosis. Lancet 2011; 378 (9785): 57-72. doi:
  6. Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Reviews 2009; 28: 369-378. doi: 10.1007/s10555-009-9188-5 12. Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science 2005; 309 (5740): 1573-1576. doi: 10.1126/science.1115079 13. BACTEC MGIT 960 User’s Manual; 2014
  7. Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes. Approved Standard M24-A2. 2nd ed. Wayne, PA, USA: CLSI; 2011
  8. Kamerbeek J, Schouls L, Kolk A, Agterveld M, Soolingen D et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology